Accelerate Diagnostics Inc (NASDAQ:AXDX) has been given an average rating of “Hold” by the six analysts that are covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $17.50.

A number of research analysts have recently commented on AXDX shares. BidaskClub raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Wednesday, August 14th. Zacks Investment Research lowered Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. BTIG Research reissued a “hold” rating on shares of Accelerate Diagnostics in a report on Sunday, May 12th. Piper Jaffray Companies lowered their price target on Accelerate Diagnostics from $22.00 to $19.00 and set a “positive” rating on the stock in a report on Friday, August 9th. Finally, ValuEngine lowered Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Thursday, July 11th.

Hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its stake in Accelerate Diagnostics by 25.1% during the fourth quarter. FMR LLC now owns 738,449 shares of the medical research company’s stock valued at $8,492,000 after buying an additional 148,099 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Accelerate Diagnostics by 331.4% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,727 shares of the medical research company’s stock valued at $100,000 after buying an additional 6,704 shares in the last quarter. Chicago Capital LLC boosted its stake in Accelerate Diagnostics by 10.6% during the second quarter. Chicago Capital LLC now owns 546,279 shares of the medical research company’s stock valued at $12,499,000 after buying an additional 52,460 shares in the last quarter. Geode Capital Management LLC boosted its stake in Accelerate Diagnostics by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 307,860 shares of the medical research company’s stock valued at $3,540,000 after buying an additional 9,188 shares in the last quarter. Finally, Griffin Asset Management Inc. boosted its stake in Accelerate Diagnostics by 11.1% during the first quarter. Griffin Asset Management Inc. now owns 484,871 shares of the medical research company’s stock valued at $10,192,000 after buying an additional 48,352 shares in the last quarter. 54.56% of the stock is owned by institutional investors and hedge funds.

NASDAQ AXDX traded down $0.23 during trading hours on Friday, hitting $17.97. The company had a trading volume of 7,706 shares, compared to its average volume of 206,593. The firm has a market cap of $986.81 million, a P/E ratio of -11.09 and a beta of 2.75. The company has a quick ratio of 18.89, a current ratio of 19.99 and a debt-to-equity ratio of 4.81. Accelerate Diagnostics has a fifty-two week low of $10.23 and a fifty-two week high of $24.75. The business has a fifty day simple moving average of $19.04 and a 200-day simple moving average of $19.66.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. The company had revenue of $1.81 million for the quarter, compared to analyst estimates of $2.71 million. Accelerate Diagnostics had a negative return on equity of 170.47% and a negative net margin of 1,293.91%. Equities analysts forecast that Accelerate Diagnostics will post -1.58 EPS for the current fiscal year.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Recommended Story: What is a Market Correction?

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.